James Eugene
Tracked across 1 events · 21 articles · First seen Sep 08, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Analyst at Verso Investment Management, provided critical commentary on the trial failure.
Sep 08, 2026 · 21 articles
ERGEN INTELLIGENCE
Track James Eugene live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard